Guanfacine
- Generic Name
- Guanfacine
- Brand Names
- Intuniv, Tenex
- Drug Type
- Small Molecule
- Chemical Formula
- C9H9Cl2N3O
- CAS Number
- 29110-47-2
- Unique Ingredient Identifier
- 30OMY4G3MK
- Background
Guanfacine, or BS 100-141, is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974.
Guanfacine was granted FDA approval on 27 October 1986.
- Indication
Guanfacine is indicated alone or as an adjunct with stimulants to treat ADHD.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Gilles de la Tourette's Syndrome, Hypertension, Migraine
- Associated Therapies
- -
ACE-D: Accelerating Cognition-guided Signatures to Enhance Translation in Depression: Clinical Trial
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 160
- Registration Number
- NCT06408246
- Locations
- 🇺🇸
Stanford Psychiatry and Behavioral Sciences Department, Palo Alto, California, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study
- Conditions
- Interventions
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 46
- Registration Number
- NCT04742673
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
The Effect of Guanfacine on Delirium in Critically Ill Patients
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 100
- Registration Number
- NCT04578886
- Locations
- 🇺🇸
University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States
Affective Dysregulation (AD) in Children With ADHD Treated by Guanfacin
- Conditions
- Interventions
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2020-04-06
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 40
- Registration Number
- NCT04016207
Guanfacine to Improve Substance Use Outcomes in Women
- Conditions
- Interventions
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Yale University
- Target Recruit Count
- 74
- Registration Number
- NCT03980184
- Locations
- 🇺🇸
The Yale Stress Center: Yale University, New Haven, Connecticut, United States
Efficacy of Guanfacine and Lidocaine Combination in Trigeminal Nerve Block for Pain Management in Trigeminal Neuropathy
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 37
- Registration Number
- NCT03865940
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Noradrenergic Add-on Therapy With Guanfacine
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 148
- Registration Number
- NCT03116126
- Locations
- 🇬🇧
Imperial Memory Unit, Charing Cross Hospital, London, United Kingdom
Guanfacine for PONV and Pain After Sinus Surgery
- Conditions
- Interventions
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 84
- Registration Number
- NCT02882854
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Treatment of OSA Associated Hypertension With Alpha 2 Agonist or Diuretic
- Conditions
- Interventions
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2020-12-04
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 41
- Registration Number
- NCT02699125
CRT-Guanfacine for SPD
- Conditions
- Interventions
- First Posted Date
- 2015-08-17
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 45
- Registration Number
- NCT02524899
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.